PLUS & PRO members may submit
guest posts and press releases.

CVS Health launches Cordavis

CVS Health today announced that it had launched Cordavis, a wholly-owned subsidiary that will work directly with manufacturers to commercialize and/or co-produce private brand biosimilar products (an FDA-approved biologic medication that is highly similar to and has no clinically meaningful differences from a biologic medicine already approved by the FDA) for the U.S. pharmaceutical market. The Cordavis products will be FDA-approved, high quality, easy for patients to use, and will help ensure a consistent long-term supply of affordable biosimilars.

As the U.S. pharmaceutical environment evolves, biosimilars represent one of the biggest opportunities for reducing drug costs for employers and consumers. Through Cordavis, CVS Health intends to develop a portfolio of products that it expects will facilitate broader access to biosimilars in the U.S. — creating more competition that drives down prices — while encouraging investment in future products. The biosimilars market in the U.S. is projected to grow from less than $10 billion in 2022 to more than $100 billion by 2029.

As its first product, Cordavis has contracted with Sandoz to commercialize and bring to market Hyrimoz (adalimumab-adaz), a biosimilar for Humira, in the first quarter of 2024 under a Cordavis private label. The list price of the Cordavis Hyrimoz will be more than 80% lower than the current list price of Humira.

“CVS Health has a history of bringing innovative solutions to the market that lower the cost of drugs and ensure people have access to the medications they need to stay healthy,” said Shawn Guertin, Chief Financial Officer, CVS Health. “Cordavis is a logical evolution for us and will help ensure sufficient supply of biosimilars in the U.S. and support this market now and in the future, while ultimately improving health outcomes and reducing costs for consumers.”

“Biosimilars are crucial to creating competition and reducing costs for specialty pharmaceuticals where drug prices are rising the fastest,” said Prem Shah, Chief Pharmacy Officer and Co-President of the Pharmacy and Consumer Wellness segment. “Through our direct involvement, we will expand the supply chain and ensure biosimilar availability in the market. We have assembled a talented team at Cordavis and look forward to the value this business will deliver to patients and payors.”

VELOCITY TALKS

SUBSCRIBE TO VELOCITY TALKS ON YOUTUBE

By Published On: August 24th, 2023Tags: ,

Share This Incite!

About the Author: Christopher Durham

Christopher Durham is the president of the Velocity Institute. Prior to this he founded the groundbreaking site My Private Brand. He is the co-founder of The Vertex Awards. He began his retail career building brands at Food Lion and Lowe’s Home Improvement. Durham has worked with retailers around the world, including Albertsons, Family Dollar, Petco, Staples, Office Depot, Best Buy, Metro Canada. Durham has published seven definitive books on private brands, including Fifty2: The My Private Brand Project and Vanguard: Vintage Originals.

2024 EVENTS

TICKETS, SPONSORSHIPS & EXPO BOOTHS NOW AVAILABLE

VELOCITY
PRIVATE BRAND + AI

FREE VIRTUAL SUMMIT

ON DEMAND

VELOCITY
INNOVATE 24

FREE VIRTUAL SUMMIT

MARCH 27, 2024

VELOCITY
CONFERENCE + EXPO

CHARLOTTE, NC

MAY 13-15, 2024

VERTEX AWARDS
EUROPE

AMSTERDAM,

THE NETHERLANDS

MAY 27, 2024

VELOCITY
EUROPE 2024

FREE VIRTUAL SUMMIT

JUNE 27, 2024

VELOCITY
SUSTAINABILITY SUMMIT 2024

PHOENIX, ARIZONA

OCTOBER 22-23, 2024

VELOCITY
BOLD BASH 2024

CHICAGO, IL

NOVEMBER 18, 2024

SPONSOR
OR EXHIBIT

AT A

VELOCITY EVENT

SPONSOR SPEAKING
OPPORTUNITIES
AVAILABLE

Title